Mode
Text Size
Log in / Sign up

Systematic review and meta-analysis of adherence to intranasal corticosteroids and oral antihistamines in adults with allergic rhinitisMost People With Allergies Skip Their Meds, New Data Shows

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note substantial geographic variation in adherence to intranasal corticosteroids and oral antihistamines in allergic rhinitis.

This systematic review and meta-analysis assessed adherence to intranasal corticosteroids and oral antihistamines in adults with allergic rhinitis. The analysis included 191,103 patients across multiple studies. Overall pooled adherence to these medications was 43%. Significant geographic variation was observed, with intranasal corticosteroid adherence at 17% in North America and 61% in Asia. Oral antihistamine adherence was 26% in North America and 48% in Northern and Western Europe.

The authors highlight substantial heterogeneity across studies and significant geographic variation in adherence rates. Self-reported adherence consistently exceeded pharmacy refill-based estimates in the included data. These measurement differences may influence the interpretation of real-world effectiveness.

Limitations include the inability to infer causation from observational adherence data and the need to avoid assuming clinical outcomes from adherence rates. The review does not report adverse events or discontinuations. Practice relevance is limited to using geographic stratification for benchmarks rather than universal targets.

Allergic rhinitis affects about 1 in 5 adults worldwide. It is not just a runny nose. It can mess with your sleep, your focus at work, and your overall quality of life.

The standard treatment is simple. Doctors usually prescribe intranasal corticosteroids (sprays that reduce inflammation in your nose) and oral antihistamines (pills that block the allergic reaction). Both work well when taken correctly.

But here is the problem. These medications only work if you use them consistently. Skipping doses means your symptoms come back. And when symptoms come back, many people assume the medication is not working. So they stop entirely.

The Old Way vs. What This Research Reveals

For years, doctors have known that patients struggle with taking medication. But most estimates came from asking patients directly. "Do you take your medicine?" Most people say yes.

But here is the twist. When researchers compared what patients said to actual pharmacy records, the numbers looked very different.

Self-reported adherence (what people tell their doctor) was consistently higher than pharmacy refill data (what people actually pick up from the drugstore). This matters because it means doctors may be getting an incomplete picture of how well their patients are managing allergies.

How Researchers Tracked Nearly 200,000 Patients

The research team looked at 12 different studies covering 191,103 adults with allergic rhinitis. They focused on two common medication types: nasal sprays and antihistamine pills.

They wanted to know one thing. How many people actually take these medications as prescribed?

The answer was clear. Overall, only 43% of patients stuck with their treatment. But the number changed dramatically depending on where patients lived and how adherence was measured.

What the Numbers Actually Say

In North America, only 17% of patients used their nasal sprays as directed. In Asia, that number jumped to 61%. For antihistamine pills, adherence ranged from 26% in North America to 48% in Northern and Western Europe.

This does not mean patients in North America are lazy or careless.

The researchers point out that healthcare systems, insurance rules, and how medications are prescribed all play a role. In some countries, getting a refill is easy and cheap. In others, it is a hassle.

The measurement method also mattered a lot. When patients reported their own use, adherence looked much higher. When researchers checked pharmacy records, the numbers dropped. This gap suggests that many patients honestly believe they are taking their medication correctly, but the data tells a different story.

But There Is a Catch

This analysis does not tell us why patients stop taking their medication. It only shows that they do.

The researchers could not track whether patients forgot, ran out of refills, stopped because of side effects, or simply decided the medication was not helping. All of those reasons matter, and all of them need different solutions.

If you have hay fever and struggle to stick with your medication, you are not alone. This is a widespread problem, not a personal failure.

Talk to your doctor honestly about how often you actually use your spray or pill. They may have strategies to help. Some options include setting phone reminders, linking your medication to a daily habit (like brushing your teeth), or asking about a different medication that fits your schedule better.

For now, no new treatment or magic pill is coming. The solution is better communication between patients and doctors, and a clearer understanding of what real-world adherence looks like.

What Happens Next

The researchers call for future studies to use standardized methods for measuring adherence. They also want more research in regions that were not well represented in this analysis.

This kind of work takes time. But it matters. When doctors have accurate data about how patients actually use medications, they can design better treatment plans. And when patients understand that skipping doses is common, they may feel more comfortable asking for help.

The bottom line is simple. Allergy medications work. But they only work if you take them. And right now, most people are not.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedMay 2026
View Original Abstract ↓
PURPOSE OF REVIEW: Medication adherence is essential for effective management of allergic rhinitis (AR), yet real-world adherence to guideline-recommended pharmacotherapies remains poorly characterized. This systematic review and meta-analysis aims to estimate pooled adherence proportions to prescribed intranasal corticosteroids and oral antihistamines in adults with AR, further stratified by adherence measurement method and geographic region. RECENT FINDINGS: Twelve studies encompassing 191,103 AR patients were included. Overall pooled adherence to both intranasal corticosteroids and oral antihistamines was 43%, with substantial heterogeneity across studies. Adherence estimates differed significantly by measurement method with self-reported adherence consistently exceeding pharmacy refill-based estimates for both medication classes. Significant geographic variation was also observed, with intranasal corticosteroid adherence ranging from 17% in North America to 61% in Asia, and oral antihistamine adherence ranging from 26% in North America to 48% in Northern and Western Europe. Peters' test did not indicate any significant publication bias and a Leave-One-Out (LOO) sensitivity analysis showed that no single study had a disproportionate effect on the overall effect size. Adherence to pharmacotherapy in AR is suboptimal, highly method-dependent, and varies significantly across geographic regions. These findings suggest that reported adherence rates are not only influenced by patients' behaviour, but also by the methods used to measure adherence and the broader healthcare environment. Integrating methodological rigour with geographic stratification provides more informative benchmarks for clinical practice and highlights the need for context-sensitive strategies to improve real-world AR management. Future research should prioritize standardized adherence measurement and prospective studies in underrepresented regions.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.